C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study
Measurement of high sensitivity CRP (hsCRP) and lipoprotein-associated phospholipase A2 (LpPLA2) provides information on systemic inflammation and stability of atherosclerotic plaques. Data analyzing the effect of smoking on these parameters are sparse. The aim of our study was the analysis of these parameters in active smokers and never-smokers. The study included 777 smokers and 1,178 never-smokers, of whom 221 and 302 died during a follow-up, respectively. The values of LpPLA2 and hsCRP were significantly higher in smokers than in never-smokers. Mortality was highest in smokers and never-smokers with elevation of both biomarkers. Multivariate adjusted hazard ratios for patients in the highest tertile of both hsCRP and LpPLA2 compared with patients in the lowest tertile of both markers were 1.85 (1.04–3.28) in never-smokers and 1.94 (1.10–3.45) in smokers. Our data confirmed the predictive value of hsCRP and LpPLA2. However, there were a relevant number of patients with an increase of only one of these parameters. Therefore, beside other risk factors for cardiovascular disease, both parameters should be determined at least in high risk patients.
KeywordsCardiovascular disease hsCRP Inflammation LpPLA2 Mortality Plaque stability Smoking
We extend our appreciation to the participants of the LURIC study. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany. LURIC has received funding from the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and from the 7th Framework Program (Atheroremo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739) of the European Union.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR (2004) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109:837–842PubMedCrossRefGoogle Scholar
- Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W (2003) Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 24:1365–1372PubMedCrossRefGoogle Scholar
- Kleber ME, Wolfert RL, De Moissl GD, Grammer TB, Dietz S, Winkelmann BR, Boehm BO, März W (2011) Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Lab 57:659–667PubMedGoogle Scholar
- Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, Lerman LO, Lerman A (2007) Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 115:2621–2627PubMedCrossRefGoogle Scholar
- National Cholesterol Education Program Expert Panel on Detection E, treatment of high blood cholesterol in A: third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421, 2002Google Scholar
- Packard CJ, O’Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO, The West of Scotland Coronary Prevention Study Group (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343:1148–1155PubMedCrossRefGoogle Scholar
- U.S. Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, pp 1–710Google Scholar